These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17301509)

  • 61. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
    Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
    Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
    Gustafsson C; Asplund K; Britton M; Norrving B; Olsson B; Marké LA
    BMJ; 1992 Dec; 305(6867):1457-60. PubMed ID: 1493390
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
    Aljutaili M; Becker C; Witt S; Holle R; Leidl R; Block M; Brachmann J; Silber S; Bestehorn K; Stollenwerk B
    BMC Health Serv Res; 2014 Jun; 14():263. PubMed ID: 24938674
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
    Ishii M; Kawai T; Tsujita K; Igarashi A; Suzuki M; Deguchi H; Fernandez J
    Circ J; 2023 Jan; 87(2):348-359. PubMed ID: 36002313
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
    Bibbins-Domingo K;
    Ann Intern Med; 2016 Jun; 164(12):836-45. PubMed ID: 27064677
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
    van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
    Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study].
    Zhang ML; Liu QP; Gong C; Wang JM; Zhou TJ; Liu XF; Shen P; Lin HB; Tang X; Gao P
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):480-487. PubMed ID: 37291924
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness of cardiovascular prevention programs in Spain.
    Plans-Rubió P
    Int J Technol Assess Health Care; 1998; 14(2):320-30. PubMed ID: 9611906
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
    Amirsadri M; Hassani A
    Daru; 2015 Dec; 23():56. PubMed ID: 26717884
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellner Y
    Pharmacoeconomics; 2006; 24(8):783-95. PubMed ID: 16898848
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
    Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
    Heeg B; van Gestel A; Hout Bv; Olsen J; Haghfelt TH
    Ugeskr Laeger; 2006 Aug; 168(35):2911-5. PubMed ID: 16982022
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
    Ann Intern Med; 2006 Mar; 144(5):I29. PubMed ID: 16520469
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.